bs-5237R [Primary Antibody]
Rabbit  Anti-phospho-CDKN1A/p21 (Thr145)  Polyclonal Antibody
www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800
DATASHEET

Host: Rabbit

Target Protein: phospho-CDKN1A/p21 (Thr145)

IR: Immunogen Range:RQ(p-T)S

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 1026

Swiss Prot: P38936

Source: KLH conjugated Synthesised phosphopeptide derived from human CDKN1A around the phosphorylation site of Thr145:RQ(p-T)S 

Purification: affinity purified by Protein A

Storage: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.

Background: This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Two alternatively spliced variants, which encode an identical protein, have been reported. Two families of cyclin dependent kinase inhibitors (CKIs) have been identified. The p21WAF1/Cip1 family inhibits all kinases involved in the G1/S transition. The p16INK4a family inhibits Cdk4 and Cdk6 specifically.

Size: 200ul

Concentration: 1mg/ml

Applications: IHC-P=1:100-500, IHC-F=1:100-500, IF=1:100-500, Flow-Cyt=3ug/Test, ELISA=1:5000-10000

Cross Reactive Species: Human,Mouse,Rat

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES
 
PRODUCT SPECIFIC PUBLICATIONS